Inici › Limfoma de Burkitt › Maine
Assaigs clínics de Limfoma de Burkitt a Maine
4 estudis de Limfoma de Burkitt busquen participants en centres de Maine.
Ciutats de Maine
Text oficial de l'estudi (anglès)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Maine Children's Cancer Program, Scarborough
ReclutantFase 2
366 Days – 46 Years · Tots els sexes · Actualitzat el 2 d’oct. 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Maine Children's Cancer Program, Scarborough
ReclutantFase 2
365 Days · Tots els sexes · Actualitzat el 25 de set. 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Eastern Maine Medical Center, Bangor
- Maine Children's Cancer Program, Scarborough
ReclutantFase 2
Edats de 1 a 30 · Tots els sexes · Actualitzat el 1 de set. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Eastern Maine Medical Center, Bangor
- Maine Children's Cancer Program, Scarborough
ReclutantFase 3
365 Days – 25 Years · Tots els sexes · Actualitzat el 25 d’ag. 2026 · NCT03959085De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.